The Oncology Institute of Hope and Innovation Announces First Clinical Trial of 2015

Share Article

The Oncology Institute of Hope and Innovation announces first clinical trial of the year.

The Oncology Institute of Hope and Innovation is proud to have access to the latest research, technology and treatment options, including clinical trials for eligible patients. The Oncology Institute is dedicated to providing comprehensive medical services to patients. In The Oncology Institute's quest to be at the forefront of the latest medical cancer research, The Oncology Institute participates in numerous clinical trials focused on various types of malignancies that may be of interest to oncology patients. The Oncology Institute is pleased to announce the opening of the following clinical trial which may benefit some patients with lung cancer.

An open-label, multicenter, single-arm, expanded access study of alectinib for patients with anaplastic lymphoma kinase rearranged non small cell lung cancer previously treated with crizotinib.

The primary objective for this study is to provide access to alectinib as treatment for patients with ALK-rearranged non-small cell lung cancer (NSCLC) previously treated with crizotinib for whom no comparable or satisfactory alternative therapy exists.

A second primary objective is to evaluate the efficacy of alectinib in patients with ALK-rearranged NSCLC previously treated with crizotinib as measured by objective response rate, complete response, partial response, in patients with measurable disease.

Any patients that feel like they qualify for this trial, or have questions regarding eligibility, please contact Hilda Agajanian at (562) 869-1201 to schedule an evaluation.

More about The Oncology Institute:
The Oncology Institute of Hope and Innovation is committed to providing superior, compassionate and state-of-the-art medical care to our patients. We offer programs to help our patients and families cope with the challenges that are brought on by cancer and strive to optimize their quality of life. Comprehensive and realistic treatment goals are tailored to every person's unique needs and decided upon in partnership with the patients and their families. We are dedicated to and excel in cancer prevention, diagnosis and education through our exceptional team of physicians, nurse practitioners, nurses, medical assistants and office staff.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Marianne Aranda
The Oncology Institute
+1 (562) 869-1201 Ext: 101
Email >
@OncologySupport
since: 07/2009
Follow >
Oncology Institute
since: 07/2009
Like >
Visit website